Search Result

Pathways Recommended:	JAK/STAT Signaling
Isoforms Recommended:	STAT5

Results for "

Stat 5

" in MedChemExpress (MCE) Product Catalog:

By Targets:	STAT (53) Adrenergic Receptor (6) Akt (8) Apoptosis (23) Aurora Kinase (3) Bcr-Abl (7) c-Kit (2) c-Myc (1) CDK (4) Checkpoint Kinase (Chk) (1) Dopamine Receptor (6) Drug Intermediate (1) EGFR (1) Endogenous Metabolite (1) ERK (2) FLT3 (18) GHSR (1) HIV (1) Interleukin Related (1) Isotope-Labeled Compounds (3) JAK (21) Ligands for Target Protein for PROTAC (1) mRNA (1) mTOR (1) p38 MAPK (5) Parasite (3) PDGFR (2) PI3K (3) PROTACs (7) Ras (1) Reactive Oxygen Species (ROS) (1) Reference Standards (2) Small Interfering RNA (siRNA) (6) Thrombopoietin Receptor (2)
By Research Areas:	Cancer (60) Cardiovascular Disease (2) Endocrinology (7) Infection (2) Inflammation/Immunology (16) Neurological Disease (5)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (2) Mouse Pre-designed siRNA Sets (2) mRNA (1) Human Pre-designed siRNA Sets (2) siRNAs (6)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: STAT

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101853

STAT5-IN-1 25+ Cited Publications	STAT	Cancer
STAT5-IN-1 is a *STAT5* inhibitor with an IC₅₀ of 47 μM for STAT5β isoform.

HY-102048

STAT5-IN-2 2 Publications Verification	STAT Apoptosis	Cancer
STAT5-IN-2 is a *STAT5* inhibitor, extracted from reference 1, example 17f. STAT5-IN-2 has potent antileukemic effect .

HY-124500

AC-4-130 5+ Cited Publications	STAT Apoptosis	Cancer
AC-4-130 is a potent STAT5 SH2 domain inhibitor. AC-4-130 directly binds to STAT5 and disrupts STAT5 activation, dimerization, nuclear translocation, and STAT5-dependent gene transcription. AC-4-130 induces cell cycle arrest and apoptosis in FLT3-ITD-driven leukemic cells. AC-4-130 has anti-cancer activity and can efficiently block pathological levels of STAT5 activity in acute myeloid leukemia (AML) .

HY-170837

STAT5-IN-3	STAT	Cancer
STAT5-IN-3 (Compound 14a) is a *STAT5* inhibitor with anticancer activity. STAT5-IN-3 blocks the tyrosine phosphorylation of *STAT5A/5B* at the Y694/699 sites and significantly reduces the expression of *STAT5B* protein, thereby inhibiting downstream gene transcription and blocking the proliferation and survival of leukemia cells. Additionally, STAT5-IN-3 holds significant value in overcoming chemotherapy resistance .

HY-RS13892

STAT5A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
STAT5A Human Pre-designed siRNA Set A contains three designed siRNAs for STAT5A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

STAT5A Human Pre-designed siRNA Set A STAT5A Human Pre-designed siRNA Set A

HY-RS19077

Stat5a Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Stat5a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Stat5a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Stat5a Mouse Pre-designed siRNA Set A Stat5a Mouse Pre-designed siRNA Set A

HY-RS25568

Stat5a Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Stat5a Rat Pre-designed siRNA Set A contains three designed siRNAs for Stat5a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Stat5a Rat Pre-designed siRNA Set A Stat5a Rat Pre-designed siRNA Set A

HY-RS13893

STAT5B Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) STAT	Others
STAT5B Human Pre-designed siRNA Set A contains three designed siRNAs for STAT5B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

STAT5B Human Pre-designed siRNA Set A STAT5B Human Pre-designed siRNA Set A

HY-RS13894

Stat5b Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Stat5b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Stat5b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Stat5b Mouse Pre-designed siRNA Set A Stat5b Mouse Pre-designed siRNA Set A

HY-RS13895

Stat5b Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Stat5b Rat Pre-designed siRNA Set A contains three designed siRNAs for Stat5b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Stat5b Rat Pre-designed siRNA Set A Stat5b Rat Pre-designed siRNA Set A

HY-131140

BD750 5 Publications Verification	JAK STAT	Inflammation/Immunology Cancer
BD750, an effective immunosuppressant and a *JAK3/STAT5* inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation, with IC₅₀ values of 1.5 μM and 1.1 μM in mouse and human T cells, respectively .

HY-16975

SH-4-54 10+ Cited Publications	STAT	Cancer
SH-4-54 is a *STAT* inhibitor that binds to STAT3 and STAT5 with K_Ds of 300, 464 nM, respectively.

HY-Y0493

HODHBt HOOBt	STAT HIV	Infection Cancer
HODHBt (HOOBt) inhibits *STAT5-SUMO* interaction by blocking SUMOylation of phosphorylated *STAT5*. HODHBt enhances the magnitude of IL-15 signaling and significantly increases the natural killer (NK) cell cytotoxicity phenotype and function and the generation of cytokine-induced memory-like (CIML) natural killer (NK) cells. HODHBt can be used for research of HIV-infection and cancer .

HY-125151

BP-1-108	STAT Apoptosis	Cancer
BP-1-108 is a selective inhibitor of *STAT5* (K_i=8.3 μM) with anticancer activity. BP-1-108 induces apoptosis of leukemia cells by inhibiting the phosphorylation of *STAT5*. BP-1-108 can be used in the study of acute myeloid leukemia and prostate cancer .

HY-12960

SKLB4771 FLT3-IN-1	FLT3 c-Kit Apoptosis	Cancer
SKLB4771 is a potent and selective Flt3 inhibitor with an IC₅₀ value of 10 nM. SKLB4771 downregulates the phosphorylation of FLT3/STAT5/ERK, blocks cell proliferation, and induces apoptosis in tumor tissue .

HY-W093114

(R)-2-Phenylmorpholine	Drug Intermediate	Others
(R)-2-Phenylmorpholine is a fragment molecule commonly used in organic synthesis and can be involved in the synthesis of STAT5/6 PROTAC degraders or inhibitors .

HY-15312

WP1066 Maximum Cited Publications 36 Publications Verification	STAT JAK Apoptosis	Cancer
WP1066 is an inhibitor of JAK2 and *STAT3, and also shows effect on STAT5* and ERK1/2, without affecting JAK1 and JAK3.

HY-120457

WYE-151650	JAK	Inflammation/Immunology
WYE-151650 is a selective JAK-3 inhibitor. WYE-151650 suppresses IL-2-induced STAT-5 phosphorylation and cell proliferation mediated by JAK-3. WYE-151650 is promising for research of autoimmune diseases .

HY-W419331

Methionyl-methionine DL-Methionyl-DL-methionine	JAK mTOR	Cancer
Methionylmethionine (Met-Met) significantly promotes α-s1 casein (α_S1-CN) expression in the mammary explants by enhancing intracellular substrate availability and activating JAK2-STAT5 and mTOR-mediated signaling pathways .

HY-169182

AK-068	Ligands for Target Protein for PROTAC STAT	Cancer
AK-068 is a *STAT6* ligand, with a K_i of 6 nM and at least >85-fold binding selectivity over STAT5. AK-068 is a ligand for target protein (STAT6) for PROTAC (HY-169179) .

HY-148748

Butyzamide 2 Publications Verification	JAK STAT p38 MAPK	Cardiovascular Disease
Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of platelets in mouse xenotransplantation assay .

HY-N0366

Sennoside B 3 Publications Verification	PDGFR	Inflammation/Immunology
Sennoside B is a potent and orally active platelet-derived growth factor (PDGF) inhibitor. Sennoside B inhibits cell proliferation and the expression of phosphorylation of PDGFR-β, STAT-5, AKT and ERK induced by PDGF-BB. Sennoside B shows gastroprotective activities. Sennoside B has the potential for the research of gastritis .

HY-108417

Debio 0617B	STAT JAK Bcr-Abl	Cancer
Debio 0617B, a multi-kinase inhibitor, reduces maintenance and self-renewal of primary human AML CD34 ⁺ stem/progenitor cells. Debio 0617B has a unique profile targeting key kinases upstream of STAT3/STAT5 signaling such as JAK, SRC, ABL, and class III/V receptor tyrosine kinases (TKs). Debio 0617B has documented efficacy in STAT3-driven solid tumors .

HY-174636

Human IL15 mRNA	mRNA	Inflammation/Immunology
Human IL15 mRNA encodes the human interleukin 15 (IL15) protein, a cytokine that regulates T and natural killer cell activation and proliferation. IL15 induces the activation of JAK kinases, as well as the phosphorylation and activation of transcription activators STAT3, STAT5, and STAT6.

HY-122101

NSC114792	JAK Apoptosis	Cancer
NSC114792 is a selective JAK3 inhibitor. NSC114792 induces apoptosis. NSC114792 decreases the protein expression of p-JAK3 and p-STAT5 .

HY-148813

AK-2292	PROTACs STAT	Cancer
AK-2292 is a potent and selective STAT5 PROTAC degrader, with a DC₅₀ of 0.10 μM. AK-2292 induces degradation of STAT5A/B proteins in vitro and in vivo. AK-2292 can induce tumor regression in acute myeloid leukemia and chronic myeloid leukemia xenograft mouse models . AK-2292 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-12987

Pimozide 5+ Cited Publications R6238	Dopamine Receptor Adrenergic Receptor STAT Parasite	Neurological Disease Endocrinology Cancer
Pimozide is a dopamine receptor antagonist, with K_is of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a K_i of 39 nM; Pimozide also inhibits *STAT3* and *STAT5*.

HY-P1453

CMD178	STAT	Cancer
CMD178 is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling and inhibits T_reg cell development .

HY-P10283

S1H	GHSR STAT	Endocrinology
S1H, a mimetic of hGH, is a human growth hormone receptor (hGHR) antagonist. S1H inhibits the interaction of hGH with hGHR. S1H inhibits phosphorylation of STAT5 in cells co-treated with hGH .

HY-P1453A

CMD178 TFA	STAT	Cancer
CMD178 TFA is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling and inhibits T_reg cell development .

HY-107429

Abrocitinib 5+ Cited Publications PF-04965842	JAK	Inflammation/Immunology
Abrocitinib (PF-04965842) is a potent, orally active and selective JAK1 inhibitor, with IC₅₀s of 29 and 803 nM for JAK1 and JAK2, respectively. Abrocitinib (PF-04965842) exhibits less active effect on TYK2 (IC₅₀, 1.253 μM), and inhibits phosphorylation of STAT1, STAT3 and STAT5 after stimulation. Effective in autoimmune disease .

HY-118532

Tyrphostin AG30 1 Publications Verification AG30	EGFR	Cancer
Tyrphostin AG30 (AG30) is a potent and selective EGFR tyrosine kinase inhibitor. Tyrphostin AG30 (AG30) selectively inhibits self renewal induction by c-ErbB, and is able to inhibit activation of STAT5 by c-ErbB in primary erythroblasts .

HY-167692

JI069	STAT	Others
JI069 is a novel JAK-STAT inhibitor that demonstrates potent activity in suppressing Th1, Th2, and Th17 differentiation while promoting iTreg differentiation. JI069 effectively inhibits STAT3 activation as well as the activation of other STATs, including STAT1, STAT5, and STAT6. JI069 has shown significant therapeutic potential in alleviating symptoms of collagen-induced arthritis in mice while inhibiting cytokine production from T cells and the phosphorylation of STAT3 in synovial cells.

HY-168730

Anticancer agent 259	STAT	Cancer
Anticancer agent 259 (Compound 3g) is a Telmisartan (HY-13955)-based cell death modulator, that interfers with the *STAT5* signaling pathway, enhances the sensitivity of drug-resistant cells to Imatinib (HY-15463) with SC₅₀ of 1.5 μM .

HY-12987S

Pimozide-d4 R6238-d₄	Dopamine Receptor Adrenergic Receptor STAT	Neurological Disease Endocrinology Cancer
Pimozide-d₄ is a deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with K_is of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a K_i of 39 nM; Pimozide also inhibits STAT3 and STAT5 .

HY-148748G

Butyzamide	JAK STAT p38 MAPK	Cardiovascular Disease
Butyzamide (GMP) is Butyzamide (HY-148748) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of platelets in mouse xenotransplantation assay .

HY-12987R

Pimozide (Standard) R6238 (Standard)	Reference Standards Dopamine Receptor Adrenergic Receptor STAT Parasite	Neurological Disease Endocrinology Cancer
Pimozide (Standard) is the analytical standard of Pimozide. This product is intended for research and analytical applications. Pimozide is a dopamine receptor antagonist, with K_is of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a K_i of 39 nM; Pimozide also inhibits *STAT3* and *STAT5*.

HY-12987S1

Pimozide-d5 N-Oxide	Isotope-Labeled Compounds Dopamine Receptor Adrenergic Receptor STAT	Neurological Disease Endocrinology Cancer
Pimozide-d₅ N-Oxide is the deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with K_is of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5 .

HY-12987S2

Pimozide-d4-1 R6238-d₄-1	Dopamine Receptor Adrenergic Receptor STAT Parasite	Neurological Disease Endocrinology Cancer
Pimozide-d₄-1 is the deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with K_is of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a K_i of 39 nM; Pimozide also inhibits STAT3 and STAT5 .

HY-169360

SD-436	PROTACs STAT	Cancer
SD-436 is a highly selective and efficacious STAT3 PROTAC degrader (DC₅₀: 0.5 μM), with IC₅₀ of 19 nM (STAT3), 270 nM (STAT1), 360 nM (STAT4), >10 μM (STAT5) and >10 μM (STAT6). SD-436 promotes ubiquitination and degradation of STAT3, and induces tumor regression. SD-436 can be used for tumor research, such as leukemia and lymphoma (Pink: STAT3 ligand (HY-169361); Blue: E3 ligase ligand (HY-43722); Black: linker (HY-147052) .

HY-107429R

Abrocitinib (Standard) PF-04965842 (Standard)	Reference Standards JAK	Inflammation/Immunology
Abrocitinib (Standard) is the analytical standard of Abrocitinib. This product is intended for research and analytical applications. Abrocitinib (PF-04965842) is a potent, orally active and selective JAK1 inhibitor, with IC₅₀s of 29 and 803 nM for JAK1 and JAK2, respectively. Abrocitinib (PF-04965842) exhibits less active effect on TYK2 (IC₅₀, 1.253 μM), and inhibits phosphorylation of STAT1, STAT3 and STAT5 after stimulation. Effective in autoimmune disease .

HY-149974

CDK8-IN-13	Apoptosis CDK	Cancer
CDK8-IN-13 is a potent, selective and orally active CDK8 inhibitor with an IC₅₀ value of 51.9 nM. CDK8-IN-13 induces apoptosis. CDK8-IN-13 decreases the expression of p-STAT1 S727 and p-STAT5 S726. CDK8-IN-13 shows antitumor activity .

HY-14756

Totrombopag	Thrombopoietin Receptor	Others
Totrombopag is an orally effective thrombopoietin receptor (TpoR) agonist. By activating TpoR, Totrombopag initiates an intracellular signaling cascade mediated by JAK2 kinase and the transcription factor Stat5, a signaling process that is the primary mechanism regulating megakaryocyte growth and differentiation into platelets. Totrombopag can be used to study platelet production and megakaryocyte biology .

HY-168339

Tyk2-IN-22	JAK	Inflammation/Immunology
Tyk2-IN-22 (Compound A8) is a selective inhibitor for tyrosine kinase 2 (Tyk2), that it inhibits Tyk2, JAK1, and JAK3 with IC₅₀s of 9.7, 148.6, and 883.3 nM, respectively. Tyk2-IN-22 inhibits the downstream *STAT5* phosphorylation .

HY-W704363

Pimozide-d5 R6238-d₅	Isotope-Labeled Compounds Dopamine Receptor Adrenergic Receptor STAT	Inflammation/Immunology Endocrinology Cancer
Pimozide-d₅ (R6238-d₅) is the deuterium labeled Pimozide (HY-12987). Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5.

HY-155746

JAK2-IN-9	JAK	Infection Inflammation/Immunology
JAK2-IN-9 (Compound A8) is a selective JAK2 inhibitor (IC₅₀: 5 nM). JAK2-IN-9 inhibits the phosphorylation of JAK2, STAT3, and STAT5. JAK2-IN-9 has metabolic stabilities. JAK2-IN-9 induces apoptosis. JAK2-IN-9 can be used for research of myeloproliferative neoplasms (MPNs) .

HY-172946

SD-2301	PROTACs STAT	Cancer
SD-2301 is a selective STAT3 PROTAC degrader. SD-2301 induces *STAT3* degradation without affecting the protein levels of other STAT family members (STAT1, STAT2, STAT4, STAT5, STAT6). SD-2301 exerts anti-tumor effects in B16F10-bearing mice. SD-2301 can be used for the study of cancer. (Pink: STAT3 ligand (HY-172947), Blue: VHL Ligand (HY-172948), Black: Linker (HY-W577012), VHL ligand-linker conjugate (HY-172949)) .

HY-174988

JAK2-IN-13	JAK STAT	Cancer
JAK2-IN-13 is a potent and orally active JAK2 inhibitor with an IC₅₀ of 54.7 nM. JAK2-IN-13 downregulates the expressions of *p-STAT3* and *p-STAT5*. JAK2-IN-13 exhibits good bioavailability and potent inhibition of rhEPO-induced extramedullary erythropoiesis and polycythemia vera. JAK2-IN-13 can be used for the study of myeloproliferative neoplasms .

HY-135041

Totrombopag choline SB-559448 choline	Thrombopoietin Receptor	Others
Totrombopag (SB-559448) choline is an orally effective thrombopoietin receptor (TpoR) agonist. By activating TpoR, Totrombopag choline initiates an intracellular signaling cascade mediated by JAK2 kinase and the transcription factor Stat5, a signaling process that is the primary mechanism regulating megakaryocyte growth and differentiation into platelets. Totrombopag choline can be used to study platelet production and megakaryocyte biology .

HY-111152

ML115 4 Publications Verification	STAT	Cancer
ML115, a molecular probe of the signal transducer, is a selective *STAT3* agonist, with an EC₅₀ of 2 nM. ML115 increases the expression of BCL3, a known *STAT3*-dependent oncogene. ML115 is inactive against the related STAT1, STAT5 and NF-κB anti-targets. ML115 counteracts the effects of Ginsenoside Rc (HY-N0042) on cell viability and inflammatory responses in LPS (HY-D1056)-stimulated H9c2 and RAW264.7 cells, while altering oxidative stress markers. ML115 can be used for the study of breast and prostate cancers .

Cat. No.	Product Name	Category	Target	Chemical Structure